Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Palisade Bio ( (PALI) ) has provided an announcement.
Palisade Bio Inc. announced the resignation of Margery Fischbein from its Board of Directors on July 2, 2025, with no disagreements cited regarding company operations. Her contributions were acknowledged by accelerating the vesting of her stock options. Subsequently, on July 7, 2025, Emil Chuang was appointed as a new director, filling the vacancy. Dr. Chuang will serve on several committees and receive stock options and compensation as per the company’s non-employee director program.
The most recent analyst rating on (PALI) stock is a Buy with a $22.50 price target. To see the full list of analyst forecasts on Palisade Bio stock, see the PALI Stock Forecast page.
Spark’s Take on PALI Stock
According to Spark, TipRanks’ AI Analyst, PALI is a Neutral.
Palisade Bio’s financial struggles dominate the overall assessment with consistent losses and negative cash flow posing significant risks. Despite a stable balance sheet due to low leverage, the lack of profitability and reliance on external funding are concerning. Technical analysis shows some short-term stability, but long-term trends are negative, and valuation metrics are weak due to the negative P/E ratio.
To see Spark’s full report on PALI stock, click here.
More about Palisade Bio
Average Trading Volume: 309,389
Technical Sentiment Signal: Strong Sell
Current Market Cap: $3.52M
For an in-depth examination of PALI stock, go to TipRanks’ Overview page.